A Post Marketing Surveillance on Piqray in Korea
This is a prospective, multicenter, open-label, non-comparative, non-interventional, observational study to assess te safety and effectiveness of Piqray in the real-world setting
Breast Cancer
OTHER: Piqray
Incidence of AEs, Incidence of AEs, including SAEs and ADRs, 24 weeks
Objective response rates (ORRs), Objective response rates (ORRs). ORR is defined as the proportion of treated patients who achieve a best overall response (BOR) of partial response (PR) or complete response (CR) according to the response evaluation criteria in solid tumors (RECIST) version 1.1., Up to 24 weeks|Prescription dose of Piqray in combination with fulvestrant, Prescription dose of Piqray in combination with fulvestrant, Up to 24 weeks
The observation duration will be up to 24 weeks after enrollment, which is sufficient to provide adequate information about the safety and effectiveness of Piqray. If the subject does not return for a follow-up visit or stops taking Piqray for any reason, all data collected until the date of the last contact of the subject will be used. Patients will be followed up (safety follow up) for 30 days afetr either 24 weeks-treatment or early withdrawal.